Search Results

Seung Min KWAK ; Hyung Jung KIM ; Dong Hwan SHIN ; Joong Hyun JANG ; Hong Lyeol LEE ; Se Kyu KIM ; Chul Min AHN ; Sung Kyu KIM ; Won Young LEE ; Kyi Beom LEE

Tuberculosis and Respiratory Diseases 1992;39(6):502-510

4.Realities of KRAS-mutated non-small cell lung cancer.

Young Joo MIN

The Korean Journal of Internal Medicine 2017;32(3):442-442

5.Prognostic significance of p53 protein expression of primary non-small cell lung cancer.

Dong Soon KIM ; Young Joo SUNG ; Ho Kee YEUN ; Bong Choon LEE ; Yeun Lim SEO ; Jong Eun JOO

Korean Journal of Medicine 1993;45(6):736-743

6.Multiple primary lung cancer: Synchronous small cell lung carcinoma and squamous cell carcinoma.

Kyeong Cheol SHIN ; Young Ran SHIM ; Jin Hong CHUNG ; Kwan Ho LEE

Korean Journal of Medicine 2005;69(2):231-233

7.Mapping 18F-Fluorodeoxyglucose Metabolism Using PET/CT for the Assessment of Treatment Response in Non-Small Cell Lung Cancer Patients Undergoing Epidermal Growth Factor Receptor Inhibitor Treatment: A Single-Centre Experience

Subapriya Suppiah ; Fathinul Fikri Ahmad Saad ; Nur Hafizah Mohad Azmi ; Abdul Jalil Nordin

Malaysian Journal of Medicine and Health Sciences 2017;13(1):9-15

Introduction: Specific mutations in the epidermal growth factor receptor (EGFR) characterize a subgroup of nonsmall cell lung cancer (NSCLC) patients that may be highly responsive to receptor inhibitor therapy. 18F-FDG PET/CT scans can map the glucose metabolism and treatment response of NSCLC. Therefore, we aimed to assess the pattern of metabolic response and outcome of inoperable NSCLC treated with epidermal growth factor receptor (EGFR) inhibitors, using 18F-FDG PET/CT scan. Methods: A retrospective study of inoperable NSCLC patients on EGFR inhibitor treatment that were referred for wholebody18F-FDG PET/CT scans was conducted based on cases scanned from January 2011 to June 2014. Comparison was made among serial attenuation-corrected fused PET/CT images for all study patients throughout the course of their treatment. Comparison based on PERCIST criteria was categorized into 4 levels ie. complete response (CMR), partial response (PMR), stable disease (SMD), progressive metabolic disease (PMD). Results: Overall, there were 5 patients identified, mean age: 57.4 years old +/- 2.9 years; The median survival time from initiation of EGFR inhibitor treatment to death was 17 months. Two patients showed initial partial metabolic response (PMR), two had progressive metabolic disease (PMD) and one had complete metabolic response (CMR) after the initiation of treatment. The patient with initial CMR had relapse and PMD 5 months later. Majority of patients eventually succumbed to their illness. Conclusions: Wholebody18F-FDG PET/CT is able to assess metabolic treatment response of NSCLC towards EGFR inhibitor treatment.
Lung Neoplasms ; Carcinoma, Non-Small-Cell Lung

8.Clinical Efficacy of Belotecan (CKD-602), Newly Developed Camptothecin Analog, in the 2nd Line Treatment of Relapsed Small Cell Lung Cancer.

Hee Jung BAN ; In Jae OH ; Kyu Sik KIM ; Jin Yung JU ; Yong Soo KWON ; Yu Il KIM ; Sung Chul LIM ; Young Chul KIM

Tuberculosis and Respiratory Diseases 2009;66(2):93-97

9.The Relationship between MDR1 Polymorphisms and the Response to Etoposide/Cisplatin Combination Chemotherapy in Small Cell Lung Cancer.

Ji Woong SOHN ; Shin Yup LEE ; Su Jung LEE ; Hyo Sung JEON ; Jae Hee LEE ; Jae Hyung PARK ; Eun Jin KIM ; Seung Ick CHA ; Chang Ho KIM ; Young Mo KANG ; Jae Tae LEE ; Tae Hoon JUNG ; Jae Yong PARK

Tuberculosis and Respiratory Diseases 2005;58(2):135-141

10.Non small cell lung cancer diagnosed by EUS guided fine needle aspiration.

Wan Suk LEE ; Dae Sung HYUN ; Sang Chae LEE ; Eun Young KIM

Korean Journal of Medicine 2003;65(5):615-617

1.A case of non small cell lung cancer presenting with systemic lupus erythematosus(SLE).

2.Treatment for Extensive stage Small cell Lung Cancer.

3.Immunohistochemical study of NSE in small cell lung cancer (SCLS) combined with serum assay.